Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors acknowledge Ascentage Pharma (Jiangsu, China) for providing olverembatinib and all physicians, and laboratory researchers for their assistance.

Author contributions

Zhijian Xiao designed the study. Yiru Yan performed the experiments. Yiru Yan, Shiqiang Qu, Jinqin Liu, Chengwen Li, and Yujiao Jia, acquired the data, analyzed, and interpreted the data, performed statistical analysis; Xiao Yan, Zefeng Xu, Tiejun Qin, Lijuan Pan, Qingyan Gao, Bing Li and Meng Jiao participated in clinical information collection. Yiru Yan, Shiqiang Qu, Robert Peter Gale and Zhijian Xiao drafted this article. All authors read and approved the final manuscript.

Patient consent

The patient gave written informed consent compliant with the Declaration of Helsinki.

Disclosure statement

RPG is a consultant to NexImmune Inc, Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC. He is Medical Director of FFF Enterprises Inc., Partner in AZAC Inc., is on the Board of Directors of the Russian Foundation for Cancer Research Support and is a member of the Scientific Advisory Board of StemRad Ltd. All other authors have no conflicts of interest to declare.

Data availability statement

The data that support the findings of this studc from the corresponding author upon reasonable request.

[email protected]

Additional information

Funding

Supported in part by CAMS Initiative Fund for Medical Sciences (Nos. 2022-I2M-1-022 and 2020-I2M-C&T-A-020), Haihe Laboratory of Cell Ecosystem Innovation Fund (22HHXBSS00033), Clinical research fund from National Clinical Research Center for Blood Diseases (Nos. 2023NCRCA0117 and 2023NCRCA0103) and National Natural Science Funds (Nos. 82170139, 82104785 and 81530008). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Center and the Ministry of Science and Technology of China (84000-51200002).